Gilead Sciences: Still the One to Beat in Hepatitis-C

Following this past weekend’s European Association for the Study of the Liver meeting in Vienna, Bernstein’s Geoffrey Porges thinks Gilead Sciences (GILD) still has an advantage over AbbVie (ABBV) and Merck (MRK). He explains why: This past weekend the EASL meeting was held in Vienna; the presentations and posters at the meeting outlined the start of the [...]